结直肠癌靶向治疗、免疫治疗耐药机制研究；

结直肠癌放疗与靶向、免疫治疗协同机制研究

Drug resistance mechanism of targeted therapy and immunotherapy in colorectal cancer

Synergistic mechanism of radiotherapy, targeted therapy and immunotherapy in colorectal cancer

同济大学附属东方医院 肿瘤科 行政副主任

中国抗癌协会多学科诊断专委会（MDD） 委员

上海市医学会肿瘤专委会 青年委员

上海市医学会肿瘤专委会 消化肿瘤协作组 委员

上海市浦东放射治疗专委会 副主任委员

Deputy director of Oncology Department of Shanghai East Hospital , Tongji University

Member of Multidisciplinary Diagnosis Committee (MDD) of Chinese anti-Cancer Association

Youth Member of Oncology Committee of Shanghai Medical Association

Member of Digestive Tumor Cooperative Group of Oncology Committee of Shanghai Medical Association

Deputy minister of Shanghai Pudong Radiotherapy Committee

Member of China Medical Education Association Committee of Radiation Oncology

Youth Member of Chinese Radiation Therapy Oncology Group

1.国家自然科学基金项目, RSAD2 通过 m6A 识别蛋白 YTHDF2 调控 IGF1R 增强结直肠癌放疗敏感性的作用和机制研究。82160468，2022.01-2025.12，35 万，在研，主持。

2. 上海市2020年度“科技创新行动计划”医学创新研究专项项目，PD1单抗联合西妥昔单抗三线治疗MSS、RAS野生型结直肠癌的临床研究。20Y11908400，2020.12.01- 2023.11.30，30万，在研，主持。

3. 2022年度浦东新区卫生系统学科建设项目-特色专病：复发和转移性结直肠癌。PWZzb2022-08，202210-2025.09，20万，在研，主持。

4. 2021年度希思科-和黄医药肿瘤研究基金，PD1单抗联合索凡替尼与FOLFIRINOX方案转化性治疗RAS突变型结肠癌的临床研究。Y-HH202102-0001，15万，在研，主持。

Fundings:

2022.01-2025.12, National Natural Science Foundation of China (No.82160468)

2020.12.01- 2023.11.30, Shanghai Science and Technology Innovation Action Plan, Medical Innovation Research Special Project (No.20Y11908400)

2022.10-2025.09, Discipline Construction Project of Pudong New Area Health System (NO.PWZzb2022-08)

2021,CSCO - Hutchison Oncology Research Fund(Y-HH202102-0001)

发表论文（Papers）：

1. Chong X, Chen J, Zheng N, Zhou Z, Hai Y, Chen S, Zhang Y, Yu Q, Yu S, Chen Z, Bao W, Quan M, Chen ZS, Zhan Y, Gao Y. PIK3CA mutations-mediated downregulation of circLHFPL2 inhibits colorectal cancer progression via upregulating PTEN. Mol Cancer. 2022 May 26;21(1):118.

2. Cui J, Quan M, Xie D, Gao Y, Guha S, Fallon MB, Chen J, Xie K. A novel KDM5A/MPC-1 signaling pathway promotes pancreatic cancer progression via redirecting mitochondrial pyruvate metabolism. Oncogene. 2020 Jan;39(5):1140-1151.

3. Chen J, Chen L, Du S, Wu J, Quan M, Yin H, Wu Y, Ye X, Liang X. High sensitive detection of circulating tumor cell by multimarker lipid magnetic nanoparticles and clinical verifications. J Nanobiotechnology. 2019 Nov 25;17(1):116.

4. Bao W, Zhu Z, Gao Y, Chen J. Transcriptome Profiling Analysis Identifies LCP1 as a Contributor for Chidamide Resistance in Gastric Cancer. Pharm Res. 2022 May;39(5):867-876.

5. Chen J, Hai Y, Hu Q, Chen C, Jiang X, Gao Y. TGF-β Signaling Activation Confers Anlotinib Resistance in Gastric Cancer. Pharm Res. 2022;10.1007/s11095-022-03461-1.

6. Chen J, Quan M, Chen Z, Zeng T, Li Y, Zhou Y, Hai Y, Gao Y. Camrelizumab in advanced or metastatic solid tumour patients with DNA mismatch repair deficient or microsatellite instability high: an open-label prospective pivotal trial. J Cancer Res Clin Oncol. 2020 Oct;146(10):2651-2657.

7. Chen J, Li L, Zhou Z, Yu S, Li Y, Gao Y.FAPP2 promotes tumor cell growth in human colon cancer through activation of Wnt signaling. Exp Cell Res. 2019 Jan 1;374(1):12-18.

8. Quan M, Chen J, Chen Z, Hai Y, Zhou Y, Chao Q, Chen C, Li H, Wang M, Gao Y. Cetuximab retreatment plus camrelizumab and liposomal irinotecan in patients with RAS wild-type metastatic colorectal cancer: Cohort B of the phase II CRACK study. Int J Cancer. 2023 May 10. doi: 0.1002/ijc.34531.